Home > Expanded Access > An Extended Access Program for Perampanel

Eisai Inc.

An Extended Access Program for Perampanel

Official Title: 
An Extended Access Program for Perampanel
Brief Summary: 
The Extended Access Program (EAP) is a managed access programme for Perampanel. The main objective of this EAP is to ensure that patients participating in studies E2007-A001-207, E2007-G000-307, or E2007-G000-235 continue to have access to perampanel until such time perampanel tablets become commercially available for the treatment of Partial Onset Seizures (POS) in the country in which they reside. This EAP will consist of 2 phases: - Screening: The patient will start the program once the Screening assessments are completed and the patient is qualified for participation. - Treatment: Additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician. Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment. Treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved Summary of Product Characteristics (SmPC). The program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of POS in each country.
Available
Partial Onset Seizures

Drug: Perampanel
Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
Other Name: E2007

Eligibility Criteria: 

Inclusion Criteria:

- Patients who are participating in either Study 207, Study 307, or Study 235 and who in the opinion of the treating physician, continue to benefit from treatment with perampanel (revised per Amendment 01)

- Patients who provide informed consent where applicable per local requirements.

- Female patients of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (e.g., a double-barrier method [condom plus spermicide, condom plus diaphragm with spermicide])

Exclusion Criteria:

- Patients residing in countries where perampanel is commercially available for the treatment of POS

- Female patients who are lactating, pregnant, or planning to become pregnant

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 12 Years
Maximum: 70 Years
Countries: 
Argentina, Australia, Belgium, Canada, Chile, Czechia, Estonia, Finland, Greece, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Netherlands, Poland, Spain, Taiwan, Thailand
Contacts: 

Eisai Eisai Medical Information
1-888-274-2378
esi_medinfo@eisai.com

Karen Searle, PhD
Study Director
Eisai Limited

Eisai Inc.
EA Number: 
Keywords: 
anti-epileptic drug, Extended Access Program, partial onset seizures, Perampanel
MeSH Terms: 
Seizures, Anticonvulsants
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.